Mymetics SA is a clinical-stage biotechnology company specializing in the development of preventive vaccines against infectious diseases. Founded in 1999 and headquartered in Geneva, Switzerland, the company applies its proprietary virosome-based delivery platform to elicit robust immune responses at mucosal surfaces. By focusing on intranasal and intravaginal administration routes, Mymetics aims to block pathogens at their primary entry points, offering new strategies for disease prevention beyond traditional injectable formulations.
The company’s pipeline encompasses both preclinical and early clinical assets targeting high-priority viral threats. Lead candidates have included a respiratory syncytial virus (RSV) vaccine designed for intranasal delivery and an investigational mucosal vaccine for influenza. Mymetics has also pursued early-stage programs in herpes simplex virus (HSV) and human papillomavirus (HPV), leveraging its virosome technology to present conserved viral epitopes in their native conformations. Collaborative research agreements with academic institutions and government agencies support antigen selection, immunogenicity studies, and process development activities.
Mymetics maintains operations and research laboratories in Switzerland, complemented by business development and regulatory affairs offices in the United States. The company’s cross-continental footprint facilitates global clinical trial planning and partnership discussions, particularly in North America and Europe. Mymetics has engaged with regulatory authorities to outline pathways for first-in-human studies, and it continues to strengthen its manufacturing capabilities through strategic alliances with contract development and manufacturing organizations (CDMOs) experienced in vaccine production.
Leadership at Mymetics is headed by President and CEO Dr. Frédéric Schaeffer, who brings over two decades of experience in immunology and vaccine research. The executive team includes experts in clinical development, regulatory affairs, and pharmaceutical manufacturing, supported by a scientific advisory board of virology and mucosal immunology specialists. Together, this team drives Mymetics’ mission to deliver safe, effective, and scalable mucosal vaccines against emerging and reemerging infectious diseases.
AI Generated. May Contain Errors.
Free MYMX Stock Alerts